SulfaphenazoleSulfaphenazole
MedChemExpress (MCE)
HY-B1218
526-08-9
99.83%
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Room temperature in continental US
may vary elsewhere.
Sulfaphenazole is a selective inhibitor of human cytochrome P450 (CYP) 2C9 enzyme. Sulfaphenazole is a cytoprotective agent against light-induced death of photoreceptors. Sulfaphenazole inhibits light-induced necrosis and mitochondrial stress-initiated apoptosis. Sulfaphenazole is an off patent sulfonamide antibiotic and demonstrates bactericidal activity through enhanced M1 macrophage activity. Sulfaphenazole can significantly reduce infarct size and restore post-ischemic coronary flow following ischemia and reperfusion.
Sulfaphenazole (10 μM
for 1 h) causes the numbers of light-induced apoptotic and necrotic cells decreased by 33 and 44%, respectively[1].
Sulfaphenazole (5.13 mg/kg
intraperitoneal injections
daily
for 8 weeks) restores endothelium-mediated relaxation in diabetic mice[2].
CYP2C9
| | | |
| | | | | |
[1]. Qing Chang, et al. Cytochrome P450 2C epoxygenases mediate photochemical stress-induced death of photoreceptors. J Biol Chem. 2014 Mar 21
289(12):8337-52. [Content Brief]
[2]. Shahrzad Elmi, et al. Sulfaphenazole treatment restores endothelium-dependent vasodilation in diabetic mice. Vascul Pharmacol. 2008 Jan
48(1):1-8. [Content Brief]
[3]. Christopher T Turner, et al. Sulfaphenazole reduces thermal and pressure injury severity through rapid restoration of tissue perfusion. Sci Rep. 2022 Jul 23
12(1):12622. [Content Brief]